Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Buzz on the Bullboards: COVID-19 Testing Plays

There are many investing plays that are attractive to serious investors and small-cap opportunists in the current market, but coronavirus movements take the cake. We’ve noted that each sector has its share of positive opportunities for both long-term and sh...
Omri Wallach | May 6, 2020 |

XPhyto Announces a PCR Testing Breakthrough

It’s the technological breakthrough that the world has been waiting for. A small Canadian life sciences company, XPhyto Therapeutics Corp. ( CSE:XPHY ) (FSE:4XT), has just announced its ability to significantly speed up testing for COVID-19 in an...
Marc Davis | December 17, 2020 |

Biotech's Mosquito Test 'Gains Market Acceptance

This West Nile virus test and others including cancer diagnostic tests in the Utah company's pipeline are discussed in an H.C. Wainwright & Co. report. In a July 31 research note, H.C. Wainwright & Co. analyst Yi Chen reported the market has increasingly adopte...
Streetwise Reports | August 6, 2019 |

Applied Genetic Tech's Shares Double on 6-Month X-Linked RP Study Results

Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and ...
Streetwise Reports | January 10, 2020 |

Why There is Still a Dire Need for COVID-19 Testing

(Click image to play video) While the tide has turned in many countries in battle against the COVID-19, the global pandemic is far from over in countries like India, for example. Thus, the need for quick, reliable COVID at-home testing is still existential. T...
Dave Jackson | June 7, 2021 |

Buzz on the Bullboards: Cannabis Tops Health Care

(Image via HEXO Corp.) How high can we get? This past week, it has been the question on the minds of traders, when a market roller coaster saw indexes hit record highs while company earnings saw major names soar and fall in equal measure. Tapping into the larges...
Stockhouse Editorial | June 16, 2021 |

The S&P 500 Signals Cleared Up – And They Lean Bullish

Yes, it has been only yesterday when we talked about the mixed signals stocks were sending out. Given yesterday’s surprise finish to their intraday resiliency, it might seem misplaced to interpret those hints as bullish. Yet, that’s exactly what...
Monica Kingsley | May 7, 2020 |

U.S. Energy Firm's Stock at 'Good Entry Point,' Rating Upgraded to Outperform

An update on this company's valuation is provided in a Raymond James report. In an Aug. 13 research note, analyst Pavel Molchanov reported that Raymond James boosted its rating on Chart Industries Inc. (GTLS:NASDAQ) to Outperform from Market Perform, "...
Streetwise Reports | August 20, 2019 |

Navidea Shares Jump 60% on Phase 2b Rheumatoid Arthritis Trial Results

Shares of Navidea Biopharmaceuticals traded 60% higher today on extremely high relative volume after the firm released data from its Phase 2b Rheumatoid Arthritis Tc 99m Tilmanocept Planar Imaging study. Developer of precision immunodiagnostic agents and immunotherape...
Streetwise Reports | October 30, 2019 |

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...
Streetwise Reports | July 2, 2020 |
1 2 3 4